Page last updated: 2024-09-05

erlotinib hydrochloride and Dermatitis Medicamentosa

erlotinib hydrochloride has been researched along with Dermatitis Medicamentosa in 109 studies

Research

Studies (109)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	46 (42.20)	29.6817
2010's	60 (55.05)	24.3611
2020's	3 (2.75)	2.80

Authors

Authors	Studies
Chmielinska, JJ; Kramer, JH; Mak, IT; Spurney, CF; Weglicki, WB	1
Alonso Garcia, M; Fabre, E; Frimodt-Moller, B; Garon, EB; Moro-Sibilot, D; Nadal, E; Nakagawa, K; Novello, S; Ponce Aix, S; Reck, M; Visseren-Grul, CM; Zimmermann, AH	1
Ando, Y; Goto, Y; Hayashi, T; Imaizumi, K; Ito, K; Kawada, K; Matsuda, H; Nishibe-Toyosato, S; Tsuge, M; Tsujii, N; Yamada, S	1
Filiou, E; Gkiozos, I; Kainis, I; Kopitopoulou, A; Nikolaou, V; Papadavid, E; Syrigos, N	1
Aubin, F; Blanc, D; Drobacheff-Thiebaut, C; Gérard, B; Jacoulet, P; Jacquin-Porretaz, C; Nardin, C; Westeel, V	1
Alvarez-Argote, J; Dasanu, CA; Lippman, SM; Plaxe, SC	1
Kuo, KY; Kwong, B; Rahman, Z	1
Chen, KL; Cheng, YP; Cho, YT; Chu, CY; Liau, JY; Sheen, YS; Yang, CW	1
Consuegra, G; Fernandez-Penas, P; Hui, R; Liu, RC; Zhao, CY	1
Boeck, S; Caca, K; Ettrich, TJ; Fischer von Weikersthal, L; Freiberg-Richter, J; Fuchs, M; Haas, M; Heinemann, V; Held, S; Kanzler, S; Kruger, S; Kullmann, F; Kunzmann, V; Lerch, MM; Reinacher-Schick, A; Schenk, M; Siveke, JT; Westphalen, CB	1
Boespflug, A; Kaya, A; Kaya, G; Saurat, JH; Saxer-Sekulic, N; Sorg, O; Thomas, L	1
Dasanu, CA; Loftus, R; Sadeghi, M	1
Kao, S; Mahendran, A; Sebaratnam, DF; Wong, XL	1
Erikson, AK; Paripati, HR; Sheedy, JT; Shoudis, SN; Sio, TT; Yu, NY	1
Hu, Y; Jia, LJ; Li, T; Zhang, J	1
Kishi, A; Kiyohara, Y; Yamazaki, N	1
Blackford, AL; Cameron, JL; Choti, MA; De Jesus-Acosta, A; Donehower, RC; Edil, BH; Ellsworth, S; Fan, KY; Hacker-Prietz, A; Herman, JM; Hidalgo, M; Hruban, RH; Laheru, DA; Le, DT; Pawlik, TM; Schulick, RD; Wild, AT; Wolfgang, CL; Wood, LD; Zheng, L	1
Cheng, PS; Lai, FJ	1
Chiu, HC; Chiu, HY	1
Bourra, H; Hassam, B	1
Buck, M; Casado, A; Coens, C; Colombo, N; Curé, H; Despierre, E; Favier, L; Ferrero, A; Green, J; Hall, M; Jimeno, A; Joly, F; Katsaros, D; Lesoin, A; Marth, C; Pujade-Lauraine, E; Ray-Coquard, I; Reed, NS; Reinthaller, A; Steer, CB; Vergote, IB	1
Alcolea, V; Aparicio, J; Corbellas, M; Diaz Beveridge, R; Fonfría, M; García, J; Giménez, A; Montalar, J; Segura, Á	1
Rerknimitr, P; Rungtrakulchai, R	1
Au, HJ; Chen, E; Dhani, N; Gill, S; Hedley, D; Kamel-Reid, S; Moore, MJ; Renouf, DJ; Tang, PA; Tran-Thanh, D; Tsao, MS; Wang, L	1
Funazaki, H; Ichida, Y; Ikeda, M; Kobayashi, M; Mitsunaga, S; Ohno, I; Okusaka, T; Okuyama, H; Saitoh, S; Shimizu, S; Shinohara, A; Takahashi, H; Takahashi, K	1
Hwang, IG; Jang, JS; Kang, JH; Kang, MH; Kim, CK; Kim, HG; Kim, HJ; Kim, SH; Lee, J; Lee, S; Oh, SY; Park, K; Park, MJ; Park, YS; Son, C; Song, KH; Sun, JM; Yi, SY	1
Boeck, S; Brockmöller, J; Hasheminasab, SM; Heinemann, V; Hichert, V; Kächele, V; Rüdiger, S; Scholl, C; Schumann, C; Seufferlein, T; Steffens, M; Stingl, JC; Tzvetkov, MV	1
Bellini, V; Bianchi, L; Lisi, P; Pelliccia, S	1
Agapito, G; Altomare, E; Arbitrio, M; Barbieri, V; Botta, C; Cannataro, M; Codispoti, S; Conforti, S; Di Martino, MT; Guzzi, PH; Iuliano, E; Scionti, F; Tagliaferri, P; Tassone, P	1
Chen, KL; Cho, YT; Chu, CY; Lin, CC; Sheen, YS; Tsai, HE; Yang, CW	1
Bukvić Mokos, Z; Kovačević, S; Paštar, Z; Pavliša, G; Rezaković, S	1
Castillo, C; Collet-Benzaquen, D; Combemale, P; de la Fouchardière, A; Desseigne, F; Fattouh, K; Provensal, AM	1
Azan, A; Bakker Schut, TC; Besse, B; Boutros, C; Caspers, PJ; Eggermont, AM; Kamsu Kom, N; Koljenović, S; Lanoy, E; Mateus, C; Mir, LM; Noordhoek Hegt, V; Paci, A; Planchard, D; Puppels, GJ; Robert, C; Routier, E; Roy, S; Seck, A; Texier, M; Tomasic, G	1
Dunsford, J	1
Chirinos, RE; Falo, LD; Geskin, LJ; Pomerantz, RG	1
Adamson, PC; Blaney, SM; Dancey, JE; Gilbertson, RJ; Hamilton, M; Ingle, AM; Jakacki, RI; Krailo, MD; Tersak, J; Voss, SD	1
Bianchi, F; Neri, I; Patrizi, A	1
Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P	1
Cholongitas, E; Ioannidou, D; Kokolakis, G	1
Bangerter, M; Brudler, O; Heinrich, B; Reimer, G	1
Brown, CW; Campbell, TM	1
Denzlinger, C; Hass, HG	1
Deplanque, G; Deray, G; Dreno, B; Janus, N; Launay-Vacher, V; Mateus, C; Morere, JF; Robert, C; Souquet, PJ	1
Alkemade, JA; Bovenschen, HJ	1
Kaley, K; Li, J; Peccerillo, J; Saif, MW	1
Dunlop, J; Eaby, B; Groves, RW; McPhelim, J; Nicolson, M; Nijjar, R; Steele, J; Thatcher, N; Ukachukwu, I	1
Afifi, Y; Benomar, S; Bouhllab, J; Boutayeb, S; Errihanni, H; Hamada, S; Hassam, B	1
Kawana, S; Mitsuishi, T; Motoki, T	1
Cattaneo, MT; Clementi, E; Ferrario, S; Filipazzi, V; Gambaro, A; Isabella, L; Oteri, A; Piazza, E; Radice, S; Tosca, N	1
Aractingi, S; Nassar, D; Soutou, B	1
Dirschka, T; Hauschild, A; Kroth, J; Wollenberg, A	1
Araújo, CM; Bezerra, M; Dias, FL; Federico, MH; Ferreira, CG; Fontão, K; Herchenhorn, D; Knust, RE; Martins, RG; Small, I; Viegas, CM	1
De Jonge, M; Guttman-Yassky, E; Iwata, KK; Krueger, JG; Matthews, L; McCarthy, S; Mita, A; Rowinsky, EK; Verweij, J	1
Amitay-Laish, I; David, M; Stemmer, SM	1
Ahn, JS; Ahn, MJ; Kim, ST; Lee, J; Park, K; Park, YH; Sun, JM	1
Kowalski, DM; Krawczyk, P; Krzakowski, M; Kucharczyk, T; Milanowski, J; Mlak, R; Wojas-Krawczyk, K	1
Anadkat, MJ; Hepper, DM; Wu, P	1
Anadkat, MJ; Balagula, Y; Lacouture, ME; Wu, PA	1
Balagula, Y; Boone, SL; Lacouture, ME; Luu, M; Patel, J; Rademaker, AW; Sullivan, P	1
Chanprapaph, K; Pongcharoen, P; Vachiramon, V	1
Chida, K; Inui, N; Matsuura, S; Nakamura, Y; Ozawa, Y; Shirai, T; Suda, T; Suganuma, H; Toyoshima, M; Yamada, T; Yasuda, K; Yokomura, K	1
Correa, PD; Rizwanullah, M; Shrimali, RK	1
Houwing, RH; Koster, ME; Lips, IM; Vonk, EJ	1
Budak, K; Pestalozzi, B; Weisshaupt, Ch	1
Fujita, S; Hata, A; Imai, Y; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Kunimasa, K; Tachikawa, R; Tomii, K; Yoshioka, H	1
Suzuki, Y; Yamamoto, T	1
Hong, D; Kurzrock, R; Munoz, J	1
Chachoua, A; Cohen, DE; de Souza, A; Wnorowski, AM	1
Böker, B; Grohé, C; Lüders, H	1
Lin, TC; Wu, PY	1
Nakamura-Wakatsuki, T; Yamamoto, T	1
Antoniou, C; Katsambas, A; Nikolaou, V; Stratigos, A; Strimpakos, AS; Syrigos, KN	1
Cheng, YP; Chiu, HY; Jee, SH; Tsai, TF	1
Abdul Razak, M; Chan, LC; Ong, CK; Tan, WC	1
Cei, M; Mumoli, N; Vitale, J	1
Llombart, B; Requena, C; Sanmartín, O	1
Aneja, M; Berg, SR; Cella, D; Gandhi, M; Hlubocky, FJ; Lacouture, ME; Wagner, LI; Webster, K	1
Arakawa, K; Fukatsu, M; Kataoka, K; Katsuno, S; Kimura, T; Kondoh, Y; Nakamura, N; Nishiyama, O; Takashima, N; Taniguchi, H; Umemura, T; Watanabe, N	1
Angelini, F; Bianchetti, S; Gamucci, T; Gemma, D; Grande, R; Mansueto, G; Narducci, F; Sperduti, I; Trombetta, G	1
Allen, PK; Amini, A; Brown, P; Chang, JY; Chen, SS; Garland, LL; Heymach, JV; Holt, J; Kim, ES; Komaki, R; Liao, Z; McGovern, SL; Munsell, MF; Stea, B; Sulman, E; Unger, W; Wefel, JS; Welsh, JW	1
Giuliani, J; Marzola, M	1
Chosidow, O; Dirschka, T; Elsner, J; Layton, A; Mancini, L; Maughan, T; Morere, JF; Santoro, A; Segaert, S; Sobrero, A; Tabernero, J; Van Cutsem, E	1
Elsner, J; Gutzmer, R; Kapp, A; Werfel, T	1
Garey, J; Kim, E; Oishi, K; Rhee, J	1
Acebo, E; Díaz-Pérez, JL; Lasa, O; Martínez de Lagrán, Z; Ratón, JA	1
Sipples, R	1
Mitra, SS; Simcock, R	1
Cozzani, E; Parodi, A; Santoro, F	1
Aguilar, A; Aspiroz, C; Cuétara, MS; del Palacio, A; Martin, L	1
Bruno, R; Eppler, SM; Hamilton, M; Lu, JF; Lum, BL; Rakhit, A; Wolf, J	1
Calarese, P; Morse, L	1
Alomar, A; Capdevila, J; García Muret, MP; Marcuello, E; Pallarés, C; Roé, E	1
Agero, AL; Benvenuto-Andrade, C; Busam, KJ; Dusza, SW; Halpern, AC; Myskowski, P	1
Aldanondo Fernández de la Mora, I; Fernández-Guarino, M; García-Millán, C; Garrido López, P; Jaén Olasolo, P; Pérez García, B	1
Bragg, J; Pomeranz, MK	1
Fernández-Guarino, M; Garrido López, P; González-García, C; Jaén, P	1
Al Hammadi, A; Gerstein, W; Tangri, N	1
Nguyen, D; Parr, AL; Steinberg, SM; Tan, AR; Yang, SX	1
Kardaun, SH; van Duinen, KF	1
Schalock, PC; Zug, KA	1
Lacouture, ME; Mitchell, EP; Perez-Soler, R; Van Cutsem, E	1
Dietrich, PY; Lübbe, J; Masouyé, I	1
Ding, K; Pater, J; Seymour, L; Shepherd, FA; Whitehead, M	1
Epstein, RJ; Leung, TW	1
Chevreau, C; Delord, JP; Deslandres, M; Sibaud, V	1
Burgin, S; Heidary, N; Naik, H	1
Cholongitas, E; Ioannidou, D; Kokolakis, GP	1
Culkin, A; Eaby, B; Lacouture, ME	1
Cruz Hernández, JJ; Delgado Fernández, C; Mezquita Pérez, L; Navarro Martín, M; Rodríguez Sánchez, C	1

Reviews

13 review(s) available for erlotinib hydrochloride and Dermatitis Medicamentosa

Article	Year
Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer. Journal of the American Academy of Dermatology, 2013, Volume: 69, Issue:3 Topics: Acneiform Eruptions; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Humans; Ichthyosis; Lung Neoplasms; Paronychia; Patient Education as Topic; Pruritus; Quinazolines	2013
Nursing management of epidermal growth factor receptor inhibitor-induced toxicities. Clinical journal of oncology nursing, 2008, Volume: 12, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diarrhea; Drug Eruptions; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Nursing Assessment; Oncology Nursing; Panitumumab; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Severity of Illness Index	2008
[Cutaneous side effects of EGFR inhibitors--appearance and management]. Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:4 Topics: Acneiform Eruptions; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hair Diseases; Humans; Ichthyosis; Mucositis; Neoplasms; Panitumumab; Paronychia; Protein Kinase Inhibitors; Quinazolines	2010
Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors. Current opinion in oncology, 2011, Volume: 23, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Molecular Targeted Therapy; Panitumumab; Protein Kinase Inhibitors; Quinazolines	2011
The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2005, Volume: 3, Issue:8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Forecasting; Humans; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Quinazolines	2005
Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents. Clinical colorectal cancer, 2005, Volume: 5 Suppl 2 Topics: Administration, Topical; Antibodies, Monoclonal; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Steroids	2005
Common side effects of anti-EGFR therapy: acneform rash. Seminars in oncology nursing, 2006, Volume: 22, Issue:1 Suppl 1 Topics: Acneiform Eruptions; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diarrhea; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Nurse's Role; Oncology Nursing; Patient Education as Topic; Quinazolines; Severity of Illness Index	2006
EGFR-targeted therapy and related skin toxicity. Seminars in oncology nursing, 2006, Volume: 22, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Female; Humans; Ichthyosis; Middle Aged; Neoplasms; Nurse's Role; Oncology Nursing; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pruritus; Quinazolines; Signal Transduction; Skin Care; Trastuzumab	2006
Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. Journal of the American Academy of Dermatology, 2006, Volume: 55, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Drug Eruptions; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Quinazolines	2006
Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:11 Suppl 5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Hair Diseases; Humans; Lapatinib; Nail Diseases; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Telangiectasis	2007
[Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors]. Annales de dermatologie et de venereologie, 2008, Volume: Spec No 1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib	2008
Chemotherapeutic agents and the skin: An update. Journal of the American Academy of Dermatology, 2008, Volume: 58, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids	2008
An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. Clinical journal of oncology nursing, 2008, Volume: 12, Issue:2 Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benchmarking; Cetuximab; Decision Trees; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Humans; Incidence; Panitumumab; Patient Selection; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Severity of Illness Index	2008

Trials

17 trial(s) available for erlotinib hydrochloride and Dermatitis Medicamentosa

Article	Year
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis. Cancer treatment and research communications, 2021, Volume: 27 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Europe; Female; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Mutation; Placebos; Progression-Free Survival; Ramucirumab; Response Evaluation Criteria in Solid Tumors; Survival Rate; United States; Young Adult	2021
The Influence of Intervening on the Pharmaceutical Consultation Targeting Outpatients with Advanced Non-small Cell Lung Cancer Receiving Erlotinib Treatment. Biological & pharmaceutical bulletin, 2021, Sep-01, Volume: 44, Issue:9 Topics: Aged; Ambulatory Care; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Medication Therapy Management; Middle Aged; Pharmacists; Professional Role; Referral and Consultation; Retrospective Studies	2021
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'. European journal of cancer (Oxford, England : 1990), 2018, Volume: 94 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Drug Eruptions; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Proportional Hazards Models; Prospective Studies; Young Adult	2018
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. International journal of radiation oncology, biology, physics, 2013, Jul-15, Volume: 86, Issue:4 Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Drug Eruptions; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Quality of Life; Quinazolines; Radiotherapy, Intensity-Modulated	2013
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Ca Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-01, Volume: 32, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Europe; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Maintenance Chemotherapy; Middle Aged; Mutation; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Signal Transduction; Watchful Waiting	2014
A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:11 Topics: Adult; Aged; Deoxycytidine; Dose-Response Relationship, Drug; Drug Eruptions; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines	2014
Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016, Volume: 24, Issue:1 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dermatologic Agents; Disease Progression; Disease-Free Survival; Drug Eruptions; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Ointments; Pancreatic Neoplasms; Protein Kinase Inhibitors; Republic of Korea; Treatment Outcome	2016
A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents. Cancer research, 2017, 01-15, Volume: 77, Issue:2 Topics: Aged; Algorithms; Antineoplastic Agents; Area Under Curve; Biomarkers; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Male; Middle Aged; Oximes; Pilot Projects; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; ROC Curve; Sensitivity and Specificity; Skin; Spectrum Analysis, Raman; Sulfonamides; Vemurafenib	2017
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-20, Volume: 26, Issue:30 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Neoplasms; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Diarrhea; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Osteosarcoma; Quinazolines; Rhabdomyosarcoma; Temozolomide	2008
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Female; Fever; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Neoplasm Metastasis; Neutropenia; Quinazolines	2009
Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. International journal of radiation oncology, biology, physics, 2010, Nov-01, Volume: 78, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Confidence Intervals; Drug Administration Schedule; Drug Eruptions; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Male; Middle Aged; Oropharyngeal Neoplasms; Quinazolines; Radiotherapy Dosage; Salvage Therapy; Survival Rate	2010
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Dendrites; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Exanthema; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Skin	2010
Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Anorexia; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome	2011
Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy of skin moisturizers and lymecycline. A phase II study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Colorectal Neoplasms; Drug Eruptions; Emollients; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymecycline; Male; Middle Aged; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Skin; Sunscreening Agents; Treatment Outcome	2013
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Mar-01, Volume: 31, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cranial Irradiation; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Quinazolines; Treatment Outcome	2013
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clinical pharmacology and therapeutics, 2006, Volume: 80, Issue:2 Topics: Adult; Aged; Algorithms; Analysis of Variance; Area Under Curve; Biotransformation; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasms; Population; Protein Kinases; Quinazolines	2006
Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:1 Topics: Acneiform Eruptions; Antineoplastic Agents; Biomarkers; Biopsy; Breast Neoplasms; Carcinoma; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Folliculitis; Gene Expression Profiling; Humans; Ki-67 Antigen; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Skin	2008

Other Studies

79 other study(ies) available for erlotinib hydrochloride and Dermatitis Medicamentosa

Article	Year
Substance P receptor blocker, aprepitant, inhibited cutaneous and other neurogenic inflammation side effects of the EGFR1-TKI, erlotinib. Molecular and cellular biochemistry, 2020, Volume: 465, Issue:1-2 Topics: Animals; Aprepitant; Drug Eruptions; Erlotinib Hydrochloride; Male; Nervous System Diseases; Neurokinin-1 Receptor Antagonists; Rats; Rats, Sprague-Dawley	2020
Erlotinib-Associated Rash in Advanced Non-Small Cell Lung Cancer: Relation to Clinicopathological Characteristics, Treatment Response, and Survival. Oncology research, 2018, Jan-19, Volume: 26, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome	2018
Cutaneous Toxicity Induced by Hibiscus Tea in a Patient Treated with Erlotinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017, Volume: 12, Issue:5 Topics: Antineoplastic Agents; Drug Eruptions; Erlotinib Hydrochloride; Female; Herb-Drug Interactions; Hibiscus; Humans; Skin; Tea	2017
Longitudinal thumbnail fissures due to erlotinib therapy for lung cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2018, Volume: 24, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Nail Diseases; Protein Kinase Inhibitors; Thumb	2018
Mitigation of epidermal growth factor receptor inhibitor-induced side effects utilizing melanin and vascular-specific lasers: A case report series. Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology, 2017, Volume: 19, Issue:5 Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Immunological; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Hemoglobins; Humans; Hypertrichosis; Intense Pulsed Light Therapy; Lasers, Dye; Male; Melanins; Middle Aged; Neoplasms	2017
Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases. JAMA dermatology, 2017, 09-01, Volume: 153, Issue:9 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Filaggrin Proteins; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines	2017
Epidermal growth factor receptor inhibitor-induced papulopustular eruption successfully treated with low-dose oral dapsone. The Australasian journal of dermatology, 2018, Volume: 59, Issue:3 Topics: Administration, Oral; Carcinoma, Non-Small-Cell Lung; Dapsone; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Facial Dermatoses; Female; Follow-Up Studies; Humans; Lung Neoplasms; Middle Aged; Scalp Dermatoses; Treatment Outcome	2018
RASopathic comedone-like or cystic lesions induced by vemurafenib: a model of skin lesions similar but not identical to those induced by dioxins MADISH. Journal of the European Academy of Dermatology and Venereology : JEADV, 2018, Volume: 32, Issue:8 Topics: Antineoplastic Agents; Chloracne; Cytochrome P-450 CYP1A1; Dioxins; Drug Eruptions; Enzyme Activation; Epidermal Cyst; Erlotinib Hydrochloride; Female; Gefitinib; Hep G2 Cells; Humans; Male; Melanoma; Protein Kinase Inhibitors; Skin Neoplasms; Vemurafenib	2018
Erlotinib-Induced Transverse Fissure-Like Skin Lesions of Fingers. Connecticut medicine, 2016, Volume: 80, Issue:7 Topics: Administration, Topical; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Fingers; Humans; Lung Neoplasms; Middle Aged; Paronychia; Protein Kinase Inhibitors; Skin Cream; Treatment Outcome	2016
Treatment of erlotinib-induced acneiform eruption with chromophore gel-assisted phototherapy. Photodermatology, photoimmunology & photomedicine, 2019, Volume: 35, Issue:3 Topics: Acneiform Eruptions; Administration, Topical; Benzoyl Peroxide; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Methylprednisolone; Middle Aged; Phototherapy	2019
Erlotinib-Associated Rash Exacerbated by Whole-Brain Radiation Therapy: A Patient's Case Report. Practical radiation oncology, 2019, Volume: 9, Issue:3 Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Disease Progression; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Face; Female; Humans; Lung Neoplasms; Radiodermatitis; Skin; Treatment Outcome	2019
[Acute Myocardial Infarction and Purpuric Drug Eruption Caused by Erlotinib Combined with Cabozantinib:Report of One Case]. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2019, Apr-28, Volume: 41, Issue:2 Topics: Anilides; Drug Eruptions; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Myocardial Infarction; Pyridines	2019
"Arrow" sign: a rapid microscopic diagnosis of hair change associated with epidermal growth factor receptor inhibitors. Journal of the American Academy of Dermatology, 2013, Volume: 69, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Hair; Humans; Male; Microscopy; Middle Aged; Quinazolines; Scalp Dermatoses	2013
Scalp pustules in a patient receiving chemotherapy. JAMA, 2013, Sep-11, Volume: 310, Issue:10 Topics: Acneiform Eruptions; Aged; Aged, 80 and over; Biopsy; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Scalp	2013
[Dermal toxicity of erlotinib]. The Pan African medical journal, 2013, Volume: 15 Topics: Drug Eruptions; Erlotinib Hydrochloride; Facial Dermatoses; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines	2013
Management of advanced pancreatic cancer with gemcitabine plus erlotinib: efficacy and safety results in clinical practice. JOP : Journal of the pancreas, 2014, Jan-10, Volume: 15, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Eruptions; Drug Evaluation; Erlotinib Hydrochloride; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome	2014
Erlotinib induced target-like purpura. Dermatology online journal, 2014, Feb-18, Volume: 20, Issue:2 Topics: Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Purpura; Quinazolines	2014
Efficacy of prophylactic minocycline treatment for skin toxicities induced by erlotinib plus gemcitabine in patients with advanced pancreatic cancer: a retrospective study. American journal of clinical dermatology, 2015, Volume: 16, Issue:3 Topics: Acneiform Eruptions; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dermatologic Agents; Drug Eruptions; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Minocycline; Pancreatic Neoplasms; Retrospective Studies	2015
High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitors. Pharmacogenomics, 2015, Volume: 16, Issue:14 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Frequency; Heterozygote; High-Throughput Nucleotide Sequencing; Humans; Inflammation; Interleukin-8; Introns; Male; Middle Aged; Polymorphism, Single Nucleotide; Signal Transduction; Survival Analysis	2015
Histopathologic features of erythematous papulopustular eruption to epidermal growth factor receptor inhibitors in cancer patients. Journal of cutaneous pathology, 2016, Volume: 43, Issue:3 Topics: Adult; Aged; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Skin	2016
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis. Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:1 Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cholecalciferol; Drug Eruptions; Erlotinib Hydrochloride; Female; Genotype; Humans; Inflammation; Lung Neoplasms; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Quality of Life; Retrospective Studies	2016
Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer. JAMA dermatology, 2016, Volume: 152, Issue:3 Topics: Acneiform Eruptions; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Compassionate Use Trials; Cross-Sectional Studies; Drug Eruptions; Erlotinib Hydrochloride; Gefitinib; Humans; Ichthyosis; Lung Neoplasms; Paronychia; Pruritus; Quinazolines; Retrospective Studies	2016
Erlotinib-induced Rosacea-like Dermatitis. Acta dermatovenerologica Croatica : ADC, 2016, Volume: 24, Issue:1 Topics: Aged; Antineoplastic Agents; Drug Eruptions; Erlotinib Hydrochloride; Humans; Male; Rosacea	2016
Necrotizing Infundibular Crystalline Folliculitis (NICF) Induced by Anti-Tumoral Therapies: Report of 2 Cases. The American Journal of dermatopathology, 2017, Volume: 39, Issue:10 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Eruptions; Erlotinib Hydrochloride; Fluorouracil; Folliculitis; Humans; Irinotecan; Lung Neoplasms; Male	2017
Acitretin for treatment of EGFR inhibitor-induced cutaneous toxic effects. Archives of dermatology, 2008, Volume: 144, Issue:7 Topics: Acitretin; Administration, Oral; Diagnosis, Differential; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Keratolytic Agents; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines	2008
Rosaceiform eruption induced by erlotinib. Dermatologic therapy, 2008, Volume: 21 Suppl 2 Topics: Acneiform Eruptions; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines	2008
How important is the pus culture obtained from epithelial growth factor receptor (EGFR) inhibitors' associated rash? International journal of dermatology, 2008, Volume: 47, Issue:11 Topics: Antineoplastic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Quinazolines; Serratia Infections; Serratia marcescens; Suppuration	2008
[EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy]. MMW Fortschritte der Medizin, 2008, Dec-04, Volume: 150, Issue:49-50 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Hair Diseases; Humans; Neoplasms; Quinazolines	2008
Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy. Journal of drugs in dermatology : JDD, 2008, Volume: 7, Issue:12 Topics: Acneiform Eruptions; Aged; Drug Eruptions; Erlotinib Hydrochloride; Folliculitis; Humans; Male; Protein Kinase Inhibitors; Psoriasis; Quinazolines	2008
Long-term treatment of advanced hepatocellular carcinoma with the tyrosine kinase inhibitor erlotinib (Tarceva)--a case report. Zeitschrift fur Gastroenterologie, 2009, Volume: 47, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Erlotinib Hydrochloride; Fatal Outcome; Follow-Up Studies; Humans; Liver Cirrhosis, Alcoholic; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Palliative Care; Quinazolines; Ultrasonography	2009
[Description of erlotinib-related skin effects management in France. Results of the PRECEDE study]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2009, Volume: 13, Issue:2 Topics: Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Female; France; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines	2009
Erlotinib-induced dermatologic side-effects. International journal of dermatology, 2009, Volume: 48, Issue:3 Topics: Acneiform Eruptions; Aged; Antineoplastic Agents; Chickenpox; Drug Eruptions; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Herpesvirus 3, Human; Humans; Protein Kinase Inhibitors; Quinazolines; Virus Activation	2009
Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer. JOP : Journal of the pancreas, 2009, May-18, Volume: 10, Issue:3 Topics: Bacteremia; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Skin; Staphylococcal Infections; Staphylococcus aureus	2009
Expert consensus on the management of erlotinib-associated cutaneous toxicity in the u.k. The oncologist, 2009, Volume: 14, Issue:8 Topics: Drug Eruptions; Erlotinib Hydrochloride; Humans; Protein Kinase Inhibitors; Quinazolines; Survival Rate; United Kingdom	2009
Hand-foot syndrome and seborrheic dermatitis-like eruption induced by erlotinib. Dermatology online journal, 2009, Nov-15, Volume: 15, Issue:11 Topics: Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dermatitis, Seborrheic; Disease Progression; Drug Eruptions; Erlotinib Hydrochloride; Facial Dermatoses; Follow-Up Studies; Hand Dermatoses; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Syndrome	2009
Erlotinib-induced skin manifestations. The Journal of dermatology, 2009, Volume: 36, Issue:12 Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines	2009
A case of bullous dermatitis induced by erlotinib. The oncologist, 2009, Volume: 14, Issue:12 Topics: Adenocarcinoma; Dermatitis; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Skin Diseases, Vesiculobullous	2009
[Cutaneous side effects of EGF receptor inhibitors]. Bulletin du cancer, 2009, Volume: 96 Suppl Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Folliculitis; Gefitinib; Humans; Nail Diseases; Panitumumab; Quinazolines; Skin	2009
Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions. The oncologist, 2010, Volume: 15, Issue:9 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Coagulase; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Staphylococcal Infections	2010
Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment. Oncology, 2010, Volume: 79, Issue:1-2 Topics: Aged; Analysis of Variance; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasm Staging; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Treatment Outcome	2010
The applicability of a predictive index for second- and third-line treatment of unselected non-small-cell lung cancer patients. Respiration; international review of thoracic diseases, 2011, Volume: 82, Issue:4 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Exons; Female; Gene Expression Regulation, Neoplastic; Humans; Karnofsky Performance Status; Lipoproteins, HDL; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Sex Factors; Survival Analysis; Time Factors; Weight Loss	2011
Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib. Journal of the American Academy of Dermatology, 2011, Volume: 64, Issue:5 Topics: Aged; Alopecia; Carcinoma, Non-Small-Cell Lung; Cicatrix; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines	2011
Higher severity grade of erlotinib-induced rash is associated with lower skin phototype. Clinical and experimental dermatology, 2011, Volume: 36, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Drug Eruptions; Erlotinib Hydrochloride; Exanthema; Female; Humans; Incidence; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Severity of Illness Index; Skin Pigmentation; United States	2011
Papulopustular eruptions in a 32-year-old woman after lung cancer treatment. Archives of dermatology, 2011, Volume: 147, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Dermatologic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Hydrocortisone; Lung Neoplasms; Metronidazole; Mupirocin; Quinazolines	2011
Valuable lessons from treatment of non-small cell lung cancer with erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. BMJ case reports, 2008, Volume: 2008 Topics: Adult; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines	2008
Erlotinib-induced rash spares previously irradiated skin. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2011, Volume: 187, Issue:8 Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Drug Eruptions; Erlotinib Hydrochloride; Fatal Outcome; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis; Radiotherapy, Adjuvant; Tomography, X-Ray Computed	2011
[Adverse effects of new oncologic therapies]. Praxis, 2011, Jul-27, Volume: 100, Issue:15 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Colonic Neoplasms; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Facial Dermatoses; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Trastuzumab	2011
Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Survival Analysis	2011
Reactive perforating collagenosis during erlotinib therapy. Acta dermato-venereologica, 2012, Volume: 92, Issue:2 Topics: Aged; Collagen Diseases; Diabetes Complications; Drug Eruptions; Erlotinib Hydrochloride; Humans; Male; Protein Kinase Inhibitors; Quinazolines; Skin Diseases	2012
Anticoagulation-induced severe bleeding in a patient receiving bevacizumab therapy. International journal of hematology, 2012, Volume: 95, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Eruptions; Drug Interactions; Erlotinib Hydrochloride; Female; Gastrointestinal Hemorrhage; Hematoma; Heparin, Low-Molecular-Weight; Humans; Middle Aged; Neoplasm Staging; Quinazolines; Severity of Illness Index; Venous Thrombosis	2012
The management of EGFR inhibitor adverse events: a case series and treatment paradigm. International journal of dermatology, 2012, Volume: 51, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Treatment Outcome	2012
[Prognostic relevance of body mass index and rash for patients with metastatic non-small-cell lung cancer under therapy with erlotinib]. Pneumologie (Stuttgart, Germany), 2012, Volume: 66, Issue:2 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Body Height; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Drug Eruptions; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sex Factors; Smoking; Statistics as Topic; Survival Analysis	2012
Painful annular pustular drug eruption induced by erlotinib in a patient with non-small cell lung cancer. Cutis, 2011, Volume: 88, Issue:6 Topics: Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Pain; Protein Kinase Inhibitors; Quinazolines	2011
Purpuric drug eruption and alopecia induced by erlotinib. Dermatology online journal, 2012, May-15, Volume: 18, Issue:5 Topics: Adenocarcinoma; Aged; Alopecia; Dermis; Drug Eruptions; Erlotinib Hydrochloride; Humans; Leg; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines	2012
Azithromycin pulses for the treatment of epidermal growth factor receptor inhibitor-related papulopustular eruption: an effective and convenient alternative to tetracyclines. Dermatology (Basel, Switzerland), 2012, Volume: 224, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azithromycin; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Male; Middle Aged; Neoplasms; Panitumumab; Pulse Therapy, Drug; Quinazolines; Retrospective Studies; Time Factors	2012
Erlotinib-induced generalized eczema craquelé and follicular rash sparing the previous radiation field. Clinical and experimental dermatology, 2012, Volume: 37, Issue:8 Topics: Adenocarcinoma; Combined Modality Therapy; Drug Eruptions; Eczema; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines	2012
Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management. The Medical journal of Malaysia, 2012, Volume: 67, Issue:2 Topics: Adenocarcinoma; Adult; Disease Progression; Drug Eruptions; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines	2012
Erlotinib-associated dermatological toxicity. QJM : monthly journal of the Association of Physicians, 2013, Volume: 106, Issue:4 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Facial Dermatoses; Female; Humans; Lung Neoplasms; Quinazolines	2013
Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin. Cutis, 2012, Volume: 90, Issue:2 Topics: Acneiform Eruptions; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Dermatologic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Isotretinoin; Male; Quinazolines	2012
The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18). Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:4 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Health Status; Humans; Male; Middle Aged; Neoplasms; Qualitative Research; Quality of Life; Quinazolines; Surveys and Questionnaires	2013
Prognosis in patients with non-small cell lung cancer who received erlotinib treatment and subsequent dose reduction due to skin rash. Onkologie, 2012, Volume: 35, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Comorbidity; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Prevalence; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome	2012
The management of skin toxicity during erlotinib in advanced non-small cell lung cancer: how much does it cost? Cutaneous and ocular toxicology, 2013, Volume: 32, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Eruptions; Erlotinib Hydrochloride; Female; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines	2013
[Cutaneous side effects of EGF-receptor inhibition and their management]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2006, Volume: 57, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Statistics as Topic	2006
[Acneiform eruption from epidermal growth factor receptor inhibitors]. Actas dermo-sifiliograficas, 2005, Volume: 96, Issue:7 Topics: Acneiform Eruptions; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Quinazolines	2005
Erlotinib induced skin rash spares skin in previous radiotherapy field. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-01, Volume: 24, Issue:16 Topics: Adenocarcinoma; Back; Brain Neoplasms; Chemotherapy, Adjuvant; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Reoperation; Skin; Thoracic Wall	2006
Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor. The Journal of dermatological treatment, 2006, Volume: 17, Issue:3 Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines	2006
Erlotinib associated with rosacea-like folliculitis and Malassezia sympodialis. The British journal of dermatology, 2006, Volume: 155, Issue:2 Topics: Aged; Antineoplastic Agents; Dermatomycoses; Drug Eruptions; Erlotinib Hydrochloride; Folliculitis; Humans; Malassezia; Male; Quinazolines; Rosacea	2006
Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. Journal of the American Academy of Dermatology, 2006, Volume: 55, Issue:3 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Quinazolines	2006
[Treatment of acneiform rash by epidermal growth factor inhibitors with oral tetracyclines]. Actas dermo-sifiliograficas, 2006, Volume: 97, Issue:8 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents; Doxycycline; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome	2006
Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab. Dermatology online journal, 2007, Jan-27, Volume: 13, Issue:1 Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Rectal Neoplasms; Rosacea	2007
[Erlotinib (Tarceva) induced severe exanthema]. Revista clinica espanola, 2007, Volume: 207, Issue:8 Topics: Biopsy; Drug Eruptions; Erlotinib Hydrochloride; Exanthema; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Skin; Time Factors	2007
Epidermal growth factor receptor inhibitor-related folliculitis. Dermatitis : contact, atopic, occupational, drug, 2007, Volume: 18, Issue:3 Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Face; Folliculitis; Humans; Lung Neoplasms; Male; Neck; Protein Kinase Inhibitors; Quinazolines	2007
Erlotinib-induced florid acneiform rash complicated by extensive impetiginization. Clinical and experimental dermatology, 2008, Volume: 33, Issue:1 Topics: Aged; Anti-Bacterial Agents; Diarrhea; Dose-Response Relationship, Drug; Drug Eruptions; Emollients; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Minocycline; Protein Kinase Inhibitors; Pruritus; Quinazolines	2008
Acneiform reaction to erlotinib. Dermatitis : contact, atopic, occupational, drug, 2007, Volume: 18, Issue:4 Topics: Acneiform Eruptions; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines	2007
Generalized xerotic dermatitis with neutrophilic spongiosis induced by erlotinib (Tarceva). Dermatology (Basel, Switzerland), 2008, Volume: 216, Issue:3 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Dermatitis; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kidney Neoplasms; Middle Aged; Neutrophils; Protein Kinase Inhibitors; Quinazolines; Skin	2008
Validation of treatment induced specific adverse effect as a predictor of treatment benefit: a case study of NCIC CTG BR21. Contemporary clinical trials, 2008, Volume: 29, Issue:4 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Time Factors	2008
Tumor resensitization to erlotinib following brief substitution of cetuximab. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:6 Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Bone Neoplasms; Cetuximab; Deoxycytidine; Drug Eruptions; Drug Interactions; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines	2008
Painful pustular eruption in the groin and the scrotum induced by erlotinib. Journal of the European Academy of Dermatology and Venereology : JEADV, 2008, Volume: 22, Issue:4 Topics: Aged; Drug Eruptions; Erlotinib Hydrochloride; Genital Diseases, Male; Groin; Humans; Male; Protein Kinase Inhibitors; Quinazolines; Scrotum; Skin Diseases, Vesiculobullous	2008
[Acneiforme rash in woman with pulmonary adenocarcinoma]. Revista clinica espanola, 2008, Volume: 208, Issue:5 Topics: Acneiform Eruptions; Adenocarcinoma; Aged; Drug Eruptions; Erlotinib Hydrochloride; Facial Dermatoses; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines	2008